

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of CANbridge Pharmaceuticals Inc. (the “**Company**”) dated June 16, 2026 (the “**Announcement**”) in relation to the service procurement framework agreement entered into between the Company and WuXi Biologics (Cayman) Inc.. Unless otherwise defined herein or the context requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among others, (i) a letter from the Board setting out the details of the WuXi Biologics Service Procurement Framework Agreement and the transactions and the annual caps contemplated thereunder, (ii) a letter from the Independent Board Committee to the Independent Shareholders, (iii) a letter from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders, (iv) a notice of the EGM, and (v) other information required under the Listing Rules is expected to be dispatched to the Shareholders within 15 business days after the publication of the Announcement. However, as additional time is required for the Company to prepare and finalise the information to be included in the Circular, the despatch date of the Circular will be postponed to on or before July 20, 2026.

By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, July 9, 2026

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.